跳至主要内容
临床试验/NCT05909761
NCT05909761招募中不适用

An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (Inebilizumab-cdon) During Pregnancy

Amgen1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年10月15日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
Amgen
入组人数
60
试验地点
1
主要终点
Number of newborns with Major Congenital Malformations (MCMs)

研究概览

简要总结

This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or within 6 months preceding conception. Pregnancy-related data, potential confounding factors and information related to pregnancy outcome will be collected. The schedule of office visits and all treatment regimens will be determined by the treating healthcare provider. Duration of the study is 10 years, at minimum.

详细描述

Acquired from Horizon in 2024.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Provide informed consent
  • Are a female of reproductive potential with a confirmed or suspected diagnosis of NMOSD
  • Have been exposed to UPLIZNA during pregnancy as defined by receipt of any dose during pregnancy or within 6 months preceding conception
  • Note: Other Protocol Defined Inclusion/

排除标准

  • 未提供

结局指标

主要结局

Number of newborns with Major Congenital Malformations (MCMs)

时间窗: Minimum of 10 years

Number of stillbirths

时间窗: Minimum of 10 years

Number of newborns with low birth weight

时间窗: Minimum of 10 years

Number of newborns with Preterm birth

时间窗: Minimum of 10 years

次要结局

  • Number of newborns with Minor Congenital Malformations(Minimum of 10 years)
  • Number of infants with developmental milestone abnormalities(Minimum of 10 years)
  • Number of infants with neurologic abnormalities(Minimum of 10 years)
  • Number of Induced or Elective Abortions(Minimum of 10 years)
  • Number of Spontaneous Abortions(Minimum of 10 years)
  • Number of infants with immune system development abnormalities(Minimum of 10 years)

研究者

发起方
Amgen
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验